Yoshihisa Kobayashi

EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs

Yoshihisa Kobayashi, Yosuke Togashi, Yasushi Yatabe et al. · Clinical Cancer Research · 2015 · 199 citations

Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro

Toshio Fujino, Yoshihisa Kobayashi, Kenichi Suda et al. · Journal of Thoracic Oncology · 2019 · 171 citations · Full text

Medicine, Pharmacology, Cancer Genomics +8

Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)

Masaki Shimoji, Shigeki Shimizu, Katsuaki Sato et al. · Lung Cancer · 2016 · 166 citations

Medicine, Pathology, Cell Death +9

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer

Ciric To, Tyler S. Beyett, Jaebong Jang et al. · Nature Cancer · 2022 · 146 citations · Full text

Therapy-resistant Mutant Forms, Medicine, Pharmacology +9

Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth

Yoshihisa Kobayashi, Tetsuya Mitsudomi, Yukinori Sakao et al. · Annals of Oncology · 2014 · 144 citations · Full text

Pulmonary Adenocarcinoma, Ground-glass Nodules, Multiple Pulmonary Nodule +8